News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Norway's Clavis Pharma ASA Signs $380 Million Cancer Drug Deal with Clovis Oncology (JOBS)


11/24/2009 6:48:11 AM

Bookmark and Share

Reuters -- Norwegian pharmaceutical company Clavis Pharma said on Tuesday it had signed a cancer drug development deal worth around $380 million with U.S.-based Clovis Oncology, boosting its shares as much as 86 percent.

Read at Reuters

Related News

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES